Print
Share
RSS
Donate
August 14, 2024
Re: Changes to the QTdrugs List and List of Drugs to Avoid in cLQTS
Dear CredibleMeds Registrants:
The AZCERT Scientific Review Committee has found substantial evidence that the recently approved orphan drug, Mavorixafor (Xolremdi® used to treat WHIM syndrome) is associated with the development of QT prolongation but lacks convincing evidence of torsades de pointes (TdP) risk. Therefore, on July 26, 2024, Mavorixafor was added to the Possible Risk of TdP category (PR) and to the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List).
The Committee also found substantial new evidence of QT prolongation with Rivastigmine (Exelon®) a drug used for the treatment of dementia. Since the Committee did not find convincing evidence of TdP, Rivastigmine has now been added to the Possible Risk of TdP category and the list of Drugs to Avoid in CLQTS.
The Committee found substantial evidence that Osimertinib (Tagrisso®) is associated with QT prolongation and TdP. Therefore, Osimertinib has been changed from the PR category to the Known Risk of TdP category.
As demonstrated by these revisions, the QTdrugs list is dynamic and changes regularly. To perform a quick search of the QTdrugs and DTA Lists, we recommend using the CredibleMeds website and/or the smartphone app (Apple or Android). Please note that the CredibleMeds Android app is temporarily unavailable but will soon be back in the Google Play App Store.
We need your help. Please consider making a contribution to support AZCERT's work to maintain the QTdrugs List, the DTA List and the CredibleMeds website. Your support makes it all possible. Click here or the button below to donate now.
Ray WoosleyMD, PhD and the Scientific Review Committee for AZCERT
Will Heise, MD, Tyler Gallo, PharmD, R. David Woosley, MPH, Joseph Lambson, PharmD